A Phase I Evaluation of SCH 900105 With Correlative Tissue Studies in the Treatment of Adult Patients With Recurrent Glioblastoma.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 17 Feb 2012
At a glance
- Drugs Ficlatuzumab (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Biomarker; Registrational
- 01 Feb 2011 Actual end date (1 Jan 2011) added as reported by ClinicalTrials.gov.
- 01 Feb 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 07 Sep 2010 New trial record